Reid Weyant Merryman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hodgkin Disease | 13 | 2023 | 1377 | 3.700 |
Why?
|
Hematopoietic Stem Cell Transplantation | 18 | 2024 | 5550 | 2.240 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2023 | 239 | 1.460 |
Why?
|
Lymphoma, Follicular | 2 | 2024 | 450 | 1.360 |
Why?
|
Transplantation, Autologous | 13 | 2024 | 2109 | 1.290 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 9 | 2024 | 1395 | 1.210 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2020 | 1373 | 0.880 |
Why?
|
Immunotherapy, Adoptive | 7 | 2024 | 1417 | 0.840 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2023 | 9207 | 0.790 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 294 | 0.670 |
Why?
|
Salvage Therapy | 4 | 2021 | 1265 | 0.620 |
Why?
|
Immune Evasion | 1 | 2019 | 357 | 0.540 |
Why?
|
Lymphoma | 3 | 2023 | 1887 | 0.520 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11586 | 0.500 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1600 | 0.430 |
Why?
|
Asparaginase | 1 | 2012 | 225 | 0.370 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 994 | 0.330 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5163 | 0.330 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13553 | 0.300 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1820 | 0.260 |
Why?
|
Transplantation Conditioning | 4 | 2021 | 1555 | 0.260 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8538 | 0.240 |
Why?
|
Schools, Medical | 1 | 2011 | 874 | 0.230 |
Why?
|
Antigens, CD19 | 2 | 2023 | 412 | 0.220 |
Why?
|
Transplantation, Homologous | 3 | 2021 | 4637 | 0.220 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 1517 | 0.220 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9101 | 0.210 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6413 | 0.210 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 124 | 0.200 |
Why?
|
Humans | 35 | 2024 | 752341 | 0.180 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6781 | 0.180 |
Why?
|
Immunotherapy | 3 | 2024 | 4601 | 0.170 |
Why?
|
Education, Medical | 1 | 2011 | 1713 | 0.160 |
Why?
|
Prognosis | 4 | 2024 | 29327 | 0.160 |
Why?
|
Retrospective Studies | 12 | 2024 | 79127 | 0.160 |
Why?
|
Health Policy | 1 | 2011 | 2656 | 0.160 |
Why?
|
Cytarabine | 1 | 2020 | 696 | 0.150 |
Why?
|
Antibodies, Bispecific | 1 | 2020 | 185 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 189 | 0.130 |
Why?
|
Central Nervous System | 1 | 2023 | 1331 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2022 | 865 | 0.120 |
Why?
|
Graft vs Host Disease | 2 | 2017 | 2963 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2023 | 2515 | 0.120 |
Why?
|
Survival Rate | 4 | 2022 | 12746 | 0.120 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7995 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2479 | 0.110 |
Why?
|
Switzerland | 2 | 2023 | 316 | 0.100 |
Why?
|
T-Lymphocytes | 3 | 2023 | 10036 | 0.100 |
Why?
|
Adult | 11 | 2024 | 216913 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2842 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 990 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3755 | 0.090 |
Why?
|
Young Adult | 4 | 2024 | 57629 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1391 | 0.090 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11064 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2782 | 0.080 |
Why?
|
Congresses as Topic | 2 | 2023 | 795 | 0.080 |
Why?
|
Treatment Outcome | 4 | 2024 | 64245 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4495 | 0.080 |
Why?
|
Neoplasms | 1 | 2017 | 21808 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6501 | 0.070 |
Why?
|
Aged | 9 | 2024 | 166562 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3599 | 0.070 |
Why?
|
Methotrexate | 1 | 2012 | 1702 | 0.060 |
Why?
|
Remission Induction | 2 | 2024 | 2367 | 0.060 |
Why?
|
Hematologic Neoplasms | 1 | 2017 | 1864 | 0.060 |
Why?
|
Female | 10 | 2024 | 386053 | 0.060 |
Why?
|
Middle Aged | 8 | 2024 | 217019 | 0.050 |
Why?
|
Adolescent | 5 | 2024 | 86765 | 0.050 |
Why?
|
Data Collection | 1 | 2011 | 3302 | 0.050 |
Why?
|
Male | 8 | 2024 | 354881 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39079 | 0.040 |
Why?
|
Recurrence | 2 | 2022 | 8420 | 0.040 |
Why?
|
Cohort Studies | 1 | 2020 | 40984 | 0.040 |
Why?
|
Canada | 1 | 2020 | 2103 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 1993 | 0.030 |
Why?
|
Infant | 1 | 2012 | 35673 | 0.020 |
Why?
|
Child, Preschool | 1 | 2012 | 41659 | 0.020 |
Why?
|
Prospective Studies | 2 | 2020 | 53807 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2022 | 58300 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10177 | 0.010 |
Why?
|
Gene Expression | 1 | 2017 | 7580 | 0.010 |
Why?
|
Child | 1 | 2012 | 78998 | 0.010 |
Why?
|
United States | 1 | 2011 | 71442 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7399 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13153 | 0.010 |
Why?
|